These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37547300)

  • 1. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
    Kalkowska DA; Wassilak SG; Wiesen E; F Estivariz C; Burns CC; Badizadegan K; Thompson KM
    Gates Open Res; 2023; 7():55. PubMed ID: 37547300
    [No Abstract]   [Full Text] [Related]  

  • 2. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
    Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
    Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
    Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
    Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
    Thompson KM; Kalkowska DA
    Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
    [No Abstract]   [Full Text] [Related]  

  • 5. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
    Thompson KM; Kalkowska DA; Badizadegan K
    Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.